Sequential method was used to determine the effective dose of Esketamine nasal drops for children with preoperative sedation and antianxiety

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072018

Enrollment

Unknown

Registered

2023-05-31

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preoperative sedation of children

Interventions

esketamine :esketamine nasal drops

Eligibility

Sex/Gender

All

Age

3 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1)ASA I-II; 2) Operation time less than 2 hours; 3) From 3-6 years old; 4) The guardian of each child signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Congenital heart disease (tetralogy of Fallot, patent ductus arteriosus, ventricular septal defect, etc.); 2) Lung diseases (lung infection, bronchial asthma, etc.); 3) rhinitis or nasal deformity; 4) Allergic to the drugs used in this subject; 5) airway difficulties.

Design outcomes

Primary

Measure	Time frame
mYRAS;Ramsay;Induction Compliance Checklist, ICC;Plasma concentration of esketamine;	—

Secondary

Measure	Time frame
heart rate;pulse oximetry;Wake-up time;Emergence agitation score;Postoperative nausea and vomiting;	—

Countries

China

Contacts

Public ContactZou Li

the Second People's Hospital of Wuhu, Anhui Province

897946585@qq.com+86 177 5655 5528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026